{
    "nctId": "NCT00741039",
    "briefTitle": "Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older",
    "officialTitle": "Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Lung Cancer, Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 126,
    "primaryOutcomeMeasure": "Determine Response Rate of Patients > or = to 65 Yrs Diagnosed",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be \\> or = to 65 years of age.\n* Patient may be an in patient or an out-patient.\n* Patient must have a diagnosis of prostate, lung, or breast cancer.\n* Patient must have a life expectancy of \\> or = to 6 months.\n* Patient must have a Karnofsky score of \\>40%\n* Patient must be willing to return to the hospital in 8-12 weeks following immunization for blood work.\n* Patients must have a platelet count of \\>75,000 for intramuscular injection.\n* Patient may be of either gender and of any ethnic background.\n* Patients must be able to understand the nature and risk of the proposed study and be able to sign consent.\n\nVolunteer eligibility:\n\n* MSKCC employee\n* Age \\> or = to 65 years of age\n* No previous diagnosis of cancer except basal cell carcinoma, resected Stage I melanoma or in situ cervical carcinoma. Volunteers may have had a prior history of other cancers \\> 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade.\n* Patients must be able to understand the nature and risk of the proposed study and be able to sign consent.\n\nExclusion Criteria:\n\n* Karnofsky score \\<40%:\n* Patients who have received an autologous or allogeneic HCT\n* Active uncontrolled bacterial or fungal infection\n* Hypersensitivity to egg protein (eggs or egg products), chicken proteins, or any component in the influenza vaccine\n* Prior history of any life-threatening reaction after previous administration of any influenza vaccine or any component such as thimerosal (inclusion of thimerosal varies among packaging)\n* Latex allergy if going to receive the influenza vaccine\n* On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy)\n* Treatment or planned treatment with cyclophosphamide, ifosphamide, or \\> or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination.\n* HIV-1,2 seropositive patients.\n* Patients not signing informed consent.\n* Patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment\n\nHealthy controls exclusion:\n\n* Volunteers ineligible to receive either vaccine\n* Volunteers unwilling or unable to sign consent\n* Hypersensitivity to egg protein (eggs or egg products), chicken proteins, or any component in the influenza vaccine\n* Latex allergy",
    "sex": "ALL",
    "minimumAge": "65 Years",
    "stdAges": "OLDER_ADULT"
}